Today: 24 January 2026
Subscribe
Browse Category

NYSE:SNY News 15 January 2026 - 17 January 2026

Merck stock price slips as FDA fast-track doubts surface before MRK earnings

Merck stock price slips as FDA fast-track doubts surface before MRK earnings

NEW YORK, Jan 16, 2026, 21:08 EST — Market closed. Shares of Merck & Co (MRK.N) dipped 1.9% Friday, closing at $108.83 following a range of $108.49 to $111.19. The stock kicked off the session at $110.63 with roughly 14.9 million shares traded. The drop came as investors digested a Reuters report revealing some drugmakers’ unease over the FDA Commissioner’s…
17 January 2026
·······
Pfizer stock edges higher as vaccine-policy jitters and obesity race frame the next catalyst

Pfizer stock edges higher as vaccine-policy jitters and obesity race frame the next catalyst

New York, Jan 15, 2026, 13:24 EST — Regular session Pfizer shares edged up roughly 0.3% to $25.67 on Thursday, finding footing after a volatile start to the year. Investors mulled over renewed discussions on U.S. vaccine policy alongside Pfizer’s growth strategy. The stock fluctuated between $25.26 and $25.67, with about 22.3 million shares changing hands. Why it matters now:…
15 January 2026
·····
Pfizer stock dips as U.S. vaccine policy fight rattles demand outlook

Pfizer stock dips as U.S. vaccine policy fight rattles demand outlook

New York, Jan 15, 2026, 11:16 EST — Regular session. Pfizer Inc. shares fell 0.6% to $25.42 in late-morning trading on Thursday, extending a choppy start to the year for the drugmaker’s stock. The stock has struggled to find a clear driver since Pfizer warned in December that 2026 would likely start “bumpy,” with lower COVID-related sales, price cuts tied…
15 January 2026
·········

Stock Market Today

  • Mirion Technologies Valuation Under Spotlight After 12% Share Price Surge
    January 23, 2026, 6:20 PM EST. Mirion Technologies (MIR) saw its stock rise approximately 12% over the past month, fueled by strong financials including annual revenue of $902.3 million and net income of $26.5 million. With revenue growth at 13.4% and net income up 63.4%, the company delivered a 46% total shareholder return over the last year. Despite a recent close at $26.69, analysts suggest a fair value of $30.50, indicating potential undervaluation based on long-term growth and new software initiatives. However, Mirion's high price-to-sales ratio of 6.8x, compared to industry peers, signals a premium that may already price in risks linked to its nuclear sector involvement and acquisition strategy.
Go toTop